Monoclonal antibody for resisting severe acute respiratory syndrome coronavirus 2 and application thereof

The invention provides a monoclonal antibody for resisting severe acute respiratory syndrome coronavirus 2 and application of the monoclonal antibody. The monoclonal antibody comprises: a heavy chain variable region complementarity determining region 1, the amino acid sequence of which is as shown i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHOU HONGWEI, CHAN FUK WOO JASPER, WEN KUN, CAI JIANPIAO, YUAN SHUOFENG, YUEN KWOK YUNG, DU QIHONG
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention provides a monoclonal antibody for resisting severe acute respiratory syndrome coronavirus 2 and application of the monoclonal antibody. The monoclonal antibody comprises: a heavy chain variable region complementarity determining region 1, the amino acid sequence of which is as shown in SEQ ID No.1; the amino acid sequence of the heavy chain variable region complementarity determining region 2 is as shown in SEQ ID No.2; the amino acid sequence of the heavy chain variable region complementarity determining region 3 is as shown in SEQ ID No.3; and/or a light chain variable region complementarity determining region 1, the amino acid sequence of which is as shown in SEQ ID No.4; the amino acid sequence of the light chain variable region complementarity determining region 2 is NAK; the amino acid sequence of the light chain variable region complementarity determining region 3 is as shown in SEQ ID No.5. The monoclonal antibody can effectively neutralize different variants, both murine and humanized